Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. APGE
7. ABBV
8. DFTX
9. USO
10. IBM

Go back to Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

Biogen (BIIB) PT Raised to $305 at Canaccord Genuity

October 23, 2019 5:14 AM EDT

Canaccord Genuity analyst Sumant Kulkarni raised the price target on Biogen (NASDAQ: BIIB) to $305.00 (from $285.00) while maintaining a Hold rating.

... More

Biogen (BIIB) PT Raised to $297 at BMO Capital

October 23, 2019 4:44 AM EDT

BMO Capital analyst George Farmer raised the price target on Biogen (NASDAQ: BIIB) to $297.00 (from $250.00) while maintaining a Market Perform rating.

The analyst comments "After a failed futility analysis reported last March, new results from the Phase 3 trials, EMERGE and ENGAGE, now support... More